The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Abstract
IMPORTANCE: A previous 2-year analysis of repeated rituximab treatment in patients with neuromyelitis optica (NMO) revealed significant improvements in relapse rates and disability. We report the findings from the longest follow-up of rituximab treatment in NMO, which provide reassurance regarding the long-term efficacy and safety of rituximab in NMO. OBJECTIVE: To report the results of rituximab treatment in patients with relapsing NMO or NMO spectrum disorder (NMOSD) for a median of 60 months. DESIGN, SETTING, AND PARTICIPANTS: Retrospective case series in an institutional referral center for multiple sclerosis, including 30 patients with relapsing NMO or NMOSD. INTERVENTIONS: After induction therapy, a single infusion of rituximab (375 mg/m2) as maintenance therapy was administered whenever the frequency of reemerging CD27+ memory B cells in peripheral blood mononuclear cells, as measured with flow cytometry, exceeded 0.05%in the first 2 years and 0.1% thereafter. MAIN OUTCOMES AND MEASURES: Annualized relapse rate (ARR), disability (Expanded Disability Status Scale score), change in anti–aquaporin 4 antibody, and safety of rituximab treatment. RESULTS: Of 30 patients, 26 (87%) exhibited a marked reduction in ARR over 5 years (mean [SD] pretreatment vs posttreatment ARR, 2.4 [1.5] vs 0.3 [1.0]). Eighteen patients (60%) became relapse free after rituximab treatment. In 28 patients (93%), the disability was either improved or stabilized after rituximab treatment. No serious adverse events leading to discontinuation were observed during follow-up. CONCLUSIONS AND RELEVANCE: Repeated treatment with rituximab in patients with NMOSD over a 5-period, using an individualized dosing schedule according to the frequency of reemerging CD27+ memory B cells, leads to a sustained clinical response with no new adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Klein, U., Rajewsky, K., & Küppers, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1679 · Cited by 1,154
An open label study of the effects of rituximab in neuromyelitis optica
Cree, B. A. C., Lamb, S., Morgan, K., Chen, A., Waubant, E., & Genain, C. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
(2008) · Archives of Neurology · doi:10.1001/archneur.65.11.noc80069 · Cited by 459
van Vollenhoven, R. F., Emery, P., Bingham, C. O., Keystone, E. C., Fleischmann, R. M., Furst, D. E., Tyson, N., Collinson, N., & Lehane, P. B. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201956 · Cited by 390
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Pellkofer, H. L., Krumbholz, M., Berthele, A., Hemmer, B., Gerdes, L. A., Havla, J., Bittner, R., Canis, M., Meinl, E., Hohlfeld, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182152881 · Cited by 296
Kim, S.-H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.154 · Cited by 295
Self-citationMemory B cells: Effectors of long‐lived immune responses
Tangye, S. G., & Tarlinton, D. M. (2009) · European Journal of Immunology · doi:10.1002/eji.200939531 · Cited by 253
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders
Jacob, A., McKeon, A., Nakashima, I., Sato, D. K., Elsone, L., Fujihara, K., & de Seze, J. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302310 · Cited by 174
Impact of rituximab on relapse rate and disability in neuromyelitis optica
Bedi, G. S., Brown, A. D., Delgado, S. R., Usmani, N., Lam, B. L., & Sheremata, W. A. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511404586 · Cited by 159
Greenberg, B. M., Graves, D. F., Remington, G. M., Hardeman, P., Mann, M., Karandikar, N. J., Stüve, O., Monson, N. L., & Frohman, E. M. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511432896 · Cited by 117
Treating rheumatoid arthritis to target: the patient version of the international recommendations
de Wit, M. P. T., Smolen, J. S., Gossec, L., & van der Heijde, D. M. F. M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146662 · Cited by 102
A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis
Owczarczyk, K. M., Lal, P. G., Abbas, A. R., Wolslegel, K., Holweg, C. T. J., Dummer, W., Kelman, A., Brunetta, P. G., Lewin‐Koh, N., Sorani, M. D., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002432 · Cited by 92
Kim, W., Lee, J. E., Li, X. F., Kim, S., Han, B.-G., Lee, B. I., Kim, J. K., Choi, K., & Kim, H. J. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511424590 · Cited by 84
Self-citationVariable responses to rituximab treatment in neuromyelitis optica (Devic’s disease)
Capobianco, M. A. N., Malucchi, S., Sapio, A. D., Gilli, F., Sala, A., Bottero, R., Marnetto, F., Bozzo, C. D., & Bertolotto, A. (2007) · Neurological Sciences · doi:10.1007/s10072-007-0823-z · Cited by 65
Variable results after rituximab in neuromyelitis optica
Lindsey, J. W., Meulmester, K. M., Brod, S. A., Nelson, F. M., & Wolinsky, J. S. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.02.017 · Cited by 63
Emery, P., Mease, P. J., Rubbert‐Roth, A., Curtis, J. R., Müller‐Ladner, U., GAYLIS, N. B., Williams, S., Reynard, M., & Tyrrell, H. E. J. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker253 · Cited by 54
Cited by
Neuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Damato, V., Evoli, A., & Iorio, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1637 · Cited by 290
Neuromyelitis Spectrum Disorders
Weinshenker, B. G., & Wingerchuk, D. M. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.12.014 · Cited by 286
Neuromyelitis optica spectrum disorders
Huda, S., Whittam, D., Bhojak, M., Chamberlain, J., Noonan, C., Jacob, A., & Kneen, R. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-2-169 · Cited by 283
Metadata
- Authors
- Kim, S.-H., Huh, S.-Y., Lee, S. J., Joung, A., & Kim, H. J.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2013-09-01
- Volume
- 70
- Issue
- 9
- Pages
- 1110
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2147750230
- Cited by
- 324
- References
- 21
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.